Nexstim Plc · OMXHEX:NXTMH
Nexstim — Redeye Diagnostics Event 2020
22 slides from Nexstim's conference presentation, Oct 21, 2020
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Nexstim Plc Corporate Presentation, Redeye Diagnostics Event, Stockholm 21 October 2020 Nexstim Plc
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Table of Contents
Table of Contents • Overview • Diagnostic ‒ Pre-surgical Mapping • Therapeutic ‒ Major Depressive Disorder (MDD) ‒ Chronic Neuropathic Pain • Business Update & Key Financials Nexstim Plc Public Presentation 3
Slide 4: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 5: Personalised Transcranial Magnetic Stimulation (TMS) Overview
Personalised Transcranial Magnetic Stimulation (TMS) Overview SmartFocus® Technology with a Highly Sophisticated 3D Navigation • Commercial-stage med tech company with a unique, proprietary Unique & Proprietary navigated neuro-stimulation technology for diagnostic and Technology therapeutic applicat
Slide 6: Proprietary Navigated TMS System Overview
Proprietary Navigated TMS System Overview Only TMS technology with ability to take the uniqueness of a patient’s brain into consideration for diagnostic and therapeutic applications Use System Application Europe US Commercial Status Navigated Brain Stimulation Installed base of over 170 Diagnostic P
Slide 7: Nexstim SmartFocus TMS in Diagnostics
Nexstim SmartFocus® TMS in Diagnostics Proprietary technology enabling substantial increase in progression- free survival in brain cancer surgery, commercially validated Nexstim Plc Public Presentation 7
Slide 8: NBS for Pre-surgical Mapping (Diagnostic)
NBS for Pre-surgical Mapping (Diagnostic) Diagnostic Only available technology on the market today NBS Significantly Improves Clinical Outcomes in World-leading Centers Rely on Nexstim‘s Pre-surgical Neurosurgery Mapping Technology NBS Selected institutions out of the 170 ones currently NBS helps su
Slide 9: NBS Commercialization
NBS Commercialization Diagnostic • Focus on increasing recurring revenue of existing significant installed base PSM Neurosurgery Addressable Market Volume (2020 H1) • Continue to leverage strong distributor organization in 700 Europe ‒ Cross-sell with NBT® • New sales development targeted through fu
Slide 10: Competitive Landscape
Competitive Landscape Diagnostic Diagnostic tools used for neurosurgery planning Type of procedure Unit price (€M) Function Market leaders Nexstim’s NBS system can be used as a diagnostic tool for brain surgery planning, as it allows very accurate Navigated Brain Stimulation System (NBS) 0.2 functio
Slide 11: Nexstim SmartFocus TMS in Depression
Nexstim SmartFocus® TMS in Depression Entering a rapidly growing market with a differentiated product Nexstim Plc Public Presentation 11
Slide 12: NBT for Depression
NBT® for Depression Therapeutic Nexstim depression business opportunity Market size estimate2 (patients) People affected by MDD globally • Major depressive disorder affects 2-5% of the population in 216m developed countries1 Patients not responding to medicines and seeking treatment • Existing psych
Slide 13: Promising Clinical Outcomes
Promising Clinical Outcomes Therapeutic Patients completing SmartFocus® rTMS Treatment of MDD • First 108 patients in Nexstim’s patient registry have completed SmartFocus® rTMS therapy for treatment of MDD at clinical sites in the US • 42% of the patients completing the treatment achieved clinical r
Slide 14: Nexstim SmartFocus TMS in Chronic Neuropathic Pain
Nexstim SmartFocus® TMS in Chronic Neuropathic Pain Nexstim Plc Public Presentation 14
Slide 15: NBT for Chronic Neuropathic Pain
NBT® for Chronic Neuropathic Pain Therapeutic Nexstim neuropathic pain business opportunity Market size of estimate2 People affected by chronic • There are about 10 million addressable neuropathic pain 285m neuropathic pain annually Patients not responding to patients in the US and Europe1 medicines
Slide 16: Nexstim Business Update
Nexstim Business Update Nexstim Plc Public Presentation 16
Slide 17: Nexstim Business Update H1 2020
Nexstim Business Update H1 2020 Business Operations • Focused on minimizing the effect of COVID-19 pandemic as well as updating Company strategy • Strong progress considering the difficult business environment ‒ Four new NBS systems sold (three in the US and one in Europe) ‒ Total of five new NBT® s
Slide 18: NBT / NBS Revenue – Existing Business
NBT® / NBS Revenue – Existing BusinessCumulative YTD Total Revenue 2018-2020 Business Operations 4 000 000 € 3 500 000 € • Steadily growing business, showing all time high 3 000 000 € figures in H1 2020 2 500 000 € • Rolling 12 months revenue has been staying well 2 000 000 € above the growing trend
Slide 19: Additional Revenue Opportunities
Additional Revenue Opportunities Business Operations Accelerated iTBS protocol revenue US Nexstim clinics revenue • Entry to the large untapped hospital inpatient TMS market in • Partnership business model opportunity with path to near- severe depression as well as post-remission outpatient term pro
Slide 20: Near-term Objectives / Milestones
Near-term Objectives / Milestones Business Operations 1 Decrease the operating loss with focus on achieving profitable revenue growth and strict management of operating expenses Start two new pilot studies in treating severe depression and chronic pain patients with accelerated iTBS therapy treatmen
Slide 21: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 22: Thank you!
Thank you! Nexstim Plc Public Presentation 22